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Real-world treatment patterns and adverse
events in metastatic renal cell carcinoma
from a large US claims database
Sumanta Pal1*, Jun Gong2, Shivani K. Mhatre3, Shih-Wen Lin3, Andy Surinach4, Sarika Ogale5, Rini Vohra6,
Herschel Wallen7 and Daniel George8
Abstract
Background: Vascular endothelial growth factor (VEGF), tyrosine kinase (TK) and mechanistic target of rapamycin
kinase (mTOR) inhibitors are common first-line (1 L) treatments for metastatic renal cell carcinoma (mRCC). Despite
treatment availability, the 5-year survival rate in patients diagnosed at the metastatic stage is only ≈ 10%. To gain
contemporary insights into RCC treatment trends that may inform clinical, scientific and payer considerations,
treatment patterns and adverse events (AEs) associated with 1 L therapy were examined in a retrospective,
longitudinal, population-based, observational study of patients with mRCC.
Methods: US administrative claims data (Truven Health MarketScan Commercial Databases) were used to assess
trends in 1 L treatment initiation in mRCC (2006–2015) and characterize patterns of individual 1 L treatments,
baseline characteristics, comorbidities and treatment-related AEs from 2011 through 2015. Outcomes were
evaluated by drug class and route of administration.
Results: Ten-year trend analysis (n = 4270) showed that TK/VEGF-directed therapy rapidly became more common
than mTOR-directed therapy, and oral treatments were favored over intravenous (IV) treatments. Overall, 1992
eligible patients initiated 1 L treatment for mRCC from 2011 through 2015: 1752 (88%) received TK/VEGF-directed
agents and 233 (12%) received mTOR-directed agents; 1674 (84%) received oral treatments, and 318 (16%) received
IV treatments. The most common 1 L treatment was sunitinib (n = 849), followed by pazopanib (n = 631),
temsirolimus (n = 157) and bevacizumab (n = 154). Patient characteristics and comorbidities, including age, diabetes
and congestive heart failure, were independent predictors of 1 L mRCC treatment choice. The three most common
potentially 1 L treatment–related AEs were nausea/vomiting (128.2 per 100 patient-years [PY]), hypertension (69 per
100 PY) and renal insufficiency (44.6 per 100 PY). A wide variety of agents were used as second-line (2 L) therapy.
Substantial latency of onset was observed for several potentially treatment-related toxicities in patients treated with
TK/VEGF- or mTOR-directed agents.
Conclusions: In the US, 1 L TK/VEGF inhibitor uptake in recent years appears largely in line with national approvals
and guidelines, with varied 2 L agent use. Although retrospective evaluation of claims data cannot assess
underlying causality, insights from these real-world RCC treatment and AE patterns will be useful in informing
medical and payer decisions.
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Background
Kidney cancer is the eighth most common cancer in the
United States [1]. Renal cell carcinoma (RCC) is the
most common type of adult kidney cancer, making up
about 90% of diagnoses [2]. Approximately 65% of pa-
tients with newly diagnosed RCC have localized disease
at the time of diagnosis, while 25 to 30% have advanced
or metastatic disease [1, 3]; approximately 20 to 40% of
patients with localized RCC will progress to metastatic
RCC (mRCC) [4]. The prognosis associated with mRCC
is poor, with a 5-year relative survival rate of approxi-
mately 8 to 12% in patients initially diagnosed with dis-
tant metastatic disease [1, 5]. Progression-free survival
(PFS) has been shown to predict overall survival (OS) in
patients with mRCC [6]; therefore, first-line (1 L) treat-
ment for mRCC is crucial to improving outcomes.
In the last decade, several tyrosine kinase (TK) inhibi-
tors, vascular endothelial growth factor (VEGF) inhibi-
tors (collectively, TK/VEGF inhibitors) and mechanistic
target of rapamycin (mTOR) inhibitors have been ap-
proved in the United States for 1 L use in patients with
mRCC. These agents have notably improved efficacy [4]
compared with interferon (IFN)-α and interleukin 2 (IL-2),
the previous standards of care [7, 8]. Sunitinib and pazo-
panib, both multitargeted TK inhibitors that also target
VEGF, have been shown to improve objective response
rate (ORR) and PFS compared with either IFN-α or pla-
cebo, respectively [9, 10], and pazopanib was also found
to be non-inferior to sunitinib with respect to PFS, with
similar OS observed [11]. For 1 L treatment of clear cell
RCC, current National Comprehensive Cancer Network
(NCCN) guidelines recommend several treatment op-
tions with distinct mechanisms of action, including suniti-
nib or pazopanib as category 1 options [8]. Since the
introduction of these agents, however, data on their use in
routine clinical practice have been limited [12–14] and have
tended to focus on specific patient subgroups or selective
treatments. With the changing landscape in the 1 L treat-
ment of mRCC, an understanding of real-world treatment
use, sequencing and associated adverse events (AEs) of
historic but widely used and recommended current
standard of care treatments is required [15, 16] and can
provide practitioner, researcher and payer insights into
the care and benefit:risk profiles of mRCC treatment.
Methods
Study objectives
The aims of this retrospective, longitudinal, population-
based, observational analysis were to (1) assess 10-year
trends in 1 L mRCC treatment initiation by drug class
and route of administration (from 2006 through 2015)
and (2) characterize the patterns of individual 1 L treat-
ments and baseline characteristics and comorbidities of
treated patients (from 2011 through 2015). Additionally,
in exploratory analyses, clinical factors and potentially
treatment-related AEs associated with 1 L treatments
during the latter period were assessed by drug class and
route of administration.
Study design and databases
US administrative claims data from the Truven Health
MarketScan Commercial Claims and Encounters (Com-
mercial) and Medicare Supplemental and Coordination
of Benefits (Medicare) Databases were used in this study.
Cross-sectional data were used for the trend analysis,
and longitudinal data were used for all other study ob-
jectives (Fig. 1). The MarketScan Research Databases
make up the largest private-sector healthcare database in
the United States and include information from
employer-sponsored plans that provide health benefits
to over 15 million people annually, including employees,
their spouses and dependents, approximately 10% of
whom are aged ≥ 65 years. All data on treatment
utilization and medical conditions were derived from re-
cords of prescription claims for treatment and medical
claims for conditions, respectively. This study used Tru-
ven MarketScan retrospective administrative claims data.
Data were de-identified and comply with the Health In-
surance Portability and Accountability Act and the 1964
Helsinki Declaration and its later amendments or com-
parable ethical standards. Thus, Institutional Review
Board approval was not required, and formal informed
consent was not obtained.
Patient populations and treatment definitions
For the 10-year trend analysis, patients aged ≥ 18 years
with mRCC who initiated 1 L treatment between January
1, 2006, and December 31, 2015, were included (Fig. 1a).
For analyses of treatment patterns, patient characteris-
tics and AEs, patients aged ≥ 18 years with mRCC who
initiated 1 L treatment between January 1, 2011, and De-
cember 31, 2015 (total study period July 1, 2010 to Sep-
tember 30, 2016), were included (Fig. 1b). The index
date was defined as the date of 1 L treatment initiation
for mRCC, and patients were followed for a minimum of
6 months until the end of continuous enrollment. Eligi-
bility criteria are shown in Table 1. Based on similar
mechanisms of action, agents were grouped as TK (suni-
tinib, sorafenib, pazopanib and axitinib)/VEGF inhibitors
(bevacizumab ± IFN-α) or mTOR-directed therapy (tem-
sirolimus and everolimus). These agents were classified
by route of administration as oral (sunitinib, sorafenib,
pazopanib, axitinib and everolimus) or intravenous (IV;
bevacizumab ± IFN-α, temsirolimus and IL-2).
Measures
Treatment duration was defined as the number of days
from the index date to either (1) the end of the treatment
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Fig. 1 Study design. a Trend analysis. b Treatment patterns, patient characteristics and AE analysis. The study periods are indicated as durations
between closed circles. The index date (date of 1 L treatment initiation for mRCC) could occur during the index period. Patients were followed up for a
minimum of 6months until the end of continuous enrollment. The end of 1 L treatment was defined as the last 1 L treatment claim date plus (1) the
number of days of supply of the oral treatments (last claim) or (2) the labeled cycle length for the IV treatments. Time to 2 L treatment (TT2T) was
defined as the initiation of a new 1 L therapy regimen > 30 days following the index date or restart of 1 L index treatment following a > 3-month gap
Table 1 Eligibility criteria (longitudinal analysis)
Patients,
n
Inclusion criteria
≥ 2 claims with ICD-9 code 189.0 or ICD-10 code C64.xx for malignant neoplasm of the kidney on separate dates (≥ 30 days apart)
during the index date period
77,565
First claim (ever) for a first-line mRCC agent (sunitinib, pazopanib, bevacizumab ± IFN-αa, temsirolimus, everolimus, sorafenib, axitinib,
interleukin 2) occurs during the index date period, within 30 days before the first mRCC claim and up to the end of the rolling index
period (patients with two different agents within 5 days of each other were excluded)
5813
Aged ≥ 18 years at index date 5788
Continuous enrollment eligibility 6 months pre-index and 6months post-index dates with no gap 2565
Total no. of patients after applying all the inclusion criteria 2565
Exclusion criteria
Evidence of TCC (≥ 1 claim) from 30 days pre-index date through the entire follow-up period. TCC was identified by receipt of agent
indicated for TCC
2426
≥ 2 claims for 1 primary cancer from 6months pre-index date through the index date (except for sites to which primary RCC com-
monly metastasizes, such as lung, bone, brain and liver)
1992
a For the combination treatment with bevacizumab + IFN-α, the index date is the first occurring claim of either agent. The other drug claim must have occurred
within a period of 30 days after the first agent claim to qualify as combination treatment. TCC transitional cell (urothelial) carcinoma
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regimen (with a ≤ 3-month gap permitted) or (2) a switch
to a new treatment after 30 days following the index date.
End of 1 L treatment was calculated as the last 1 L treat-
ment claim date plus (1) the number of days’ supply of
oral treatments (last claim) or (2) the labeled cycle length
for the IV treatments. In the event of a change to a
new treatment within 30 days of the initial index date,
followed by a subsequent refill of the second drug,
the second drug was considered the 1 L index drug
and initiation of the second drug was then defined as
the 1 L index date. Time to 2 L treatment (TT2T) was de-
fined as the initiation of a new treatment more than 30
days following the index date or restart of 1 L index treat-
ment following a > 3-month gap. Baseline comorbidities
were identified and incorporated into the modified Deyo-
Charlson Comorbidity Index (DCCI) score (including
non-cancer comorbidities), whereby a higher score reflects
a high comorbidity burden [17, 18]. Secondary metastases
were identified using ICD-9/ICD-10-CM codes and cate-
gorized as lung (197.0–197.3, C78.0-C78.3), liver (197.7,
C78.7), brain (198.3, 198.4, C79.3, C79.49), bone (198.5,
C79.5) and other sites.
Potentially treatment-related AEs were identified using
corresponding International Classification of Diseases
(ICD), Ninth Revision and ICD, Tenth Revision, Clinical
Modification codes in the administrative claims data that
occurred during the treatment duration up to 30 days
after the last 1 L drug claim. Such codes are likely asso-
ciated with medical attention, though administrative
claims databases are unable to provide definitive causal-
ity. The AEs evaluated in this study were chosen from
searching the product labels for each of the drugs de-
scribed, and only those that were reported to be grade 3
or 4 severity and occurring with a > 5% incidence were
included [19–25]. Additional AEs, such as diarrhea, fa-
tigue/asthenia and hand-foot syndrome, which are com-
monly associated with checkpoint inhibitors, were also
included in order to provide historical estimates for the
targeted therapies (Additional file 1: Table S1).
Statistical analysis
All analyses were assessed as a function of the 1 L index
treatment, including drug class and route of administration.
Categorical variables were reported as counts and percent-
ages, and continuous variables were reported as means with
standard deviations or medians with interquartile ranges
(Q1–Q3). For the 10-year trend analysis, the proportion of
patients receiving the index treatment by drug class and
route of administration each year was determined.
Treatment patterns were evaluated as the number and
percentage of patients receiving each 1 L treatment and
switching to the corresponding second-line (2 L) treat-
ment, the duration of 1 L treatment and TT2T.
Kaplan-Meier methods (median, 95% CI) were used for
the duration of 1 L treatment and TT2T. The duration
of 1 L treatment was evaluated to measure the difference
in time from the index date to the end of 1 L treatment,
with an event defined as discontinuation of 1 L treat-
ment and switch to a 2 L treatment or discontinuation
of 1 L treatment > 3months prior to the enrollment eligi-
bility end date (for patients who did not switch to a 2 L
therapy). Patients who discontinued 1 L treatment within
3months of the enrollment eligibility end date were cen-
sored at the enrollment eligibility end date. For TT2T
evaluation, an event was defined as a switch to a 2 L treat-
ment. Patients who did not switch were censored at the
end of 1 L treatment or the end of continuous enrollment,
whichever was earlier.
Differences in baseline patient characteristics by 1 L
treatment class (TK/VEGF inhibitor vs mTOR inhibitor)
and route of administration (oral vs IV) were compared
using a univariate t test and χ2 test (or Fisher exact test
when appropriate) for continuous and categorical vari-
ables, respectively. Variables found to be statistically sig-
nificant (P < 0.2) in the univariate analyses were used in
the multivariate logistic regression to model the odds of
choosing the drug class or route of administration. Irre-
spective of the P value in the univariate analysis, age, sex
and index year were covariates in the multivariate analysis.
AEs were reported as incidence rate per 100
patient-years (IR per 100 PY) in the total population and
in subpopulations by drug class and route of administra-
tion. IR was calculated as the number of patients with at
least one AE after the index date, divided by the total PY
at risk. If a patient did not have an AE, his/her
person-time was counted up to 30 days after the end of
1 L treatment or the end of eligibility, whichever oc-
curred first. A washout period of 30 days prior to the
index date was applied to exclude patients with
pre-existing AEs of interest when identifying incidence
of non-chronic AEs. For chronic conditions, such as
hypertension, hypotension, hepatitis, thyroid disorders,
renal insufficiency, adrenal insufficiency and myasthenia
gravis, a 365-day washout period was applied to identify
true incident events.
Results
Ten-year trends in 1 L treatment initiation for mRCC:
cross-sectional analysis
Between 325 and 508 patients were evaluated each year
from 2006 through 2015 (Fig. 2). During the 10-year
study period, TK/VEGF-directed treatments were much
more commonly initiated than were mTOR-directed or
IL-2 treatments. Initiation of TK/VEGF-directed agents
ranged from 91 to 95.7% from 2006 through 2009,
dropped to 70.5% in 2009 and ranged from 71.5 to
84.5% between 2009 and 2015 (Fig. 2a). Starting in 2009
and extending through 2015, a downward trend for
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sunitinib (61.8–35.1%) and an upward trend for pazopa-
nib (0.4–38.9%) were observed (Fig. 2b). Initiation of
VEGF-directed therapy, consisting primarily of bevacizu-
mab monotherapy, ranged from 3.3 to 10.1% (2006–
2015), without any distinct trend. mTOR inhibitor use,
predominantly temsirolimus, increased rapidly from
2.6% in 2008 to 21.7% in 2009 followed by a downward
trend to 8.8% in 2015. During the study period, oral
treatments were also much more common that IV
treatments, although initiation of oral treatments dropped
from 95.7 to 73.6% and that of IV treatments increased
from 4.3 to 26.4% between 2006 and 2009. After 2009, oral
initiation ranged from 76.2 to 87.3% and IV initiation
ranged from 12.7 to 23.8% (Fig. 2a).
Baseline clinical and demographic characteristics and 1 L
treatment patterns: longitudinal analysis
Overall, 1992 patients initiated 1 L treatment for mRCC
from 2011 through 2015 and were eligible for the longitu-
dinal analysis (Table 1). The cohort had a median
(Q1–Q3) follow-up of 15.6 (10.2–25.9) months. The me-
dian age was 62 years, and the majority of patients were
male (70%) and largely from urban areas (82%). The mean
modified DCCI score was 0.7, and 63% of patients had no
reported comorbidities. The most common comorbidities
(in > 10% of patients) were diabetes (27%), chronic kidney
disease (20%), liver disease (18%) and chronic obstructive
pulmonary disease (12.6%). Characteristics of 1 L treat-
ment subgroups are shown in Table 2.
a
b
Fig. 2 Trends in 1 L treatment for mRCC by drug class and route of administration (2006–2015). a Trends by drug class and route of administration. TK/VEGF
inhibitors included sunitinib, pazopanib, sorafenib, axitinib and bevacizumab ± IFN-α. mTOR treatments included temsirolimus and everolimus. Orally
administered agents included sunitinib, pazopanib, sorafenib, axitinib and everolimus; IV treatments included bevacizumab ± IFN-α, temsirolimus and
interleukin 2. For the oral (blue line) vs IV (orange line) comparison, the percentage of each group sums to 100% for each year. For the TK/VEGF (grey line) vs
mTOR (yellow line) comparison, the percentage of each group may sum to < 100% because interleukin 2 was not included (accounts for < 1% of patients in
each year). b Trends by individual treatment. Trends are plotted as a single value for the entire year, and approximate timings for US FDA approvals are
indicated by diamond symbols in part b (pre-2006 approvals are shown adjacent to the y-axis). Approvals plotted include 1 L sunitinib (January 26, 2006), 1 L
pazopanib (October 19, 2009), 2 L sorafenib (December 20, 2005), 2 L axitinib (January 27, 2012), 1 L bevacizumab ± IFN-α (July 31, 2009), 1 L temsirolimus
(May 30, 2007), 2 L everolimus (March 30, 2009) and 1 L interleukin 2 (May 5, 1992). In each given year, the percentage of patients receiving each indicated
agent sums to 100%
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Table 2 Key baseline characteristics of patients initiating 1 L RCC treatment (2011–2015): drug class and administration route
Characteristic TK/VEGF inhibitor
(n = 1752)
mTOR inhibitor
(n = 233)
Oral
(n = 1674)
IV
(n = 318)
n % n % n % n %
Age at diagnosis, median (Q1–Q3), years 62 (56–70) 62 (56–71) 61 (56–69) 64 (57–76)
Male 1220 69.6 166 71.2 1176 70.3 215 67.6
Employment status
Active 568 32.4 69 29.6 563 33.6 79 24.8
Retiree 652 37.2 78 33.5 617 36.9 113 35.5
Long-term disability 11 0.6 1 0.4 8 0.5 4 1.3
Other/unknown 521 29.7 85 36.5 486 29.0 122 38.4
Region
Northeast 327 18.7 33 14.2 303 18.1 57 17.9
North Central 467 26.7 52 22.3 451 26.9 68 21.4
South 645 36.8 104 44.6 622 37.2 131 41.2
West 296 16.9 40 17.2 280 16.7 59 18.6
Unknown 17 1.0 4 1.7 18 1.1 3 0.9
Metropolitan statistical area
Urban 1424 81.3 195 83.7 1359 81.2 267 84.0
Rural 328 18.7 38 16.3 315 18.8 51 16.0
Insurance plan type
Comprehensive 313 17.9 45 19.3 288 17.2 70 22.0
HMO 204 11.6 22 9.4 189 11.3 38 12.0
POS 130 7.4 17 7.3 120 7.2 28 8.8
PPO 926 52.9 125 53.7 896 53.5 158 49.7
Other 179 10.2 24 10.3 181 10.8 24 7.6
Insurance type
Commercial 1120 63.9 142 70.0 1100 65.7 169 53.1
Medicare 632 36.1 91 39.1 574 34.3 149 46.9
Index year
2011 350 20.0 78 33.5 341 20.4 88 27. 7
2012 350 20.0 62 26.6 333 19.9 80 25.2
2013 392 22.4 25 10.7 373 22.3 45 14.2
2014 327 18.7 38 16.3 309 18.5 58 18.2
2015 333 19.0 30 12.9 318 19.0 47 14.8
Mean DCCI score (Q1–Q3) 0.70 (0–1) 0.76 (0–1) 0.66 (0–1) 0.93 (0–1)
Comorbidities
Diabetes 484 27.6 48 20.6 442 26.4 90 28.3
CKD 346 19.8 54 23.2 317 18.9 84 26.4
Liver disease 307 17.5 40 17.2 306 18.3 45 14.2
COPD 217 12.4 33 14.2 212 12.7 39 12.3
CHF 113 6.5 37 15.9 111 6.6 40 12.6
Secondary metastatic sites
Lung 798 45.6 101 43.4 804 48.0 99 31.1
Liver 181 10.3 39 16.7 186 11.1 34 10.7
Brain 161 9.2 25 10.7 162 9.7 26 8.2
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Treatment patterns are included in Table 3. A total of
1752 patients (88%) received TK/VEGF inhibitor treat-
ment, 233 (12%) received mTOR inhibitor treatment,
1674 (84%) received oral treatment and 318 (16%) re-
ceived IV treatment. The most common 1 L treatment
was sunitinib (n = 849), followed by pazopanib (n = 631),
temsirolimus (n = 157) and bevacizumab (n = 149). A
total of 154 patients were treated with bevacizumab, but
only 3% (n = 5) received bevacizumab in combination
with IFN-α. Baseline characteristics by agent are shown
in Additional file 1: Tables S2 to S4.
Factors potentially associated with drug class or route
of administration were evaluated. Multivariate analyses
comparing baseline characteristics of patients treated
with TK/VEGF and mTOR inhibitors showed that pa-
tients with either baseline congestive heart failure
(CHF), secondary bone metastases or secondary liver
metastases and those who started 1 L treatment in 2011
or 2012 (vs 2015) were more likely to receive mTOR
inhibitors (Fig. 3a). Conversely, patients with baseline
diabetes were more likely to receive TK/VEGF-directed
agents than those without (Fig. 3a). In multivariate ana-
lyses comparing oral vs IV treatments, patients who had
baseline secondary lung metastases or other baseline
metastases (other than lung/liver/brain/bone) were more
likely to receive oral therapy than those who did not.
Non-retired patients and those who started 1 L treat-
ment in 2011 or 2012 (vs 2015) were more likely to re-
ceive IV than oral treatment (Fig. 3b).
1 L treatment duration, TT2T and characterization of 2 L
treatments: longitudinal analysis
Among the 1992 patients treated with 1 L targeted
therapy, the median duration of 1 L treatment was
5.9 months (Table 3). The median duration of 1 L
TK/VEGF-directed (6.3 months) or oral (6.6 months)
treatment was longer than that of 1 L mTOR-directed
(3.9 months) or IV (3.4 months) treatment. The median
Table 2 Key baseline characteristics of patients initiating 1 L RCC treatment (2011–2015): drug class and administration route
(Continued)
Characteristic TK/VEGF inhibitor
(n = 1752)
mTOR inhibitor
(n = 233)
Oral
(n = 1674)
IV
(n = 318)
n % n % n % n %
Bone 469 26.8 85 36.5 479 28.6 76 23.9
Others 696 39.7 100 42.9 704 42.1 97 30.5
Nephrectomy prior to treatment
Any nephrectomy 395 22.6 47 20.2 390 23.3 53 16.7
Cytoreductive nephrectomy 380 21.7 41 17.6 377 22.5 45 14.2
Data are n and % unless otherwise indicated. CHF congestive heart failure, CKD chronic kidney disease, COPD chronic obstructive pulmonary disease, DCCI Deyo-
Charlson Comorbidity Index, HMO health maintenance organization, POS point-of-service, PPO preferred provider organization, Q quartile
Table 3 1 L treatment patterns, duration and TT2T switch: drug class, administration route and agents
1 L treatment Patients, n Median duration of 1 L treatment (95% CI), monthsa Median TT2T (95% CI), monthsa
All patients 1992 5.9 (5.5, 6.4) 9.1 (8.5, 10.0)
Class
TK/VEGF inhibitor 1752 6.3 (5.8, 6.7) 9.8 (8.9, 10.4)
mTOR inhibitor 233 3.9 (3.4, 4.8) 6.0 (4.6, 7.1)
Route of administration
Oral 1674 6.6 (6.0, 7.3) 9.4 (8.6, 10.2)
IV 318 3.4 (2.7, 3.9) 7.3 (6.0, 9.9)
Agent
Sunitinib (TK; oral) 849 6.5 (5.9, 7.6) 9.4 (8.5, 10.3)
Sorafenib (TK; oral) 62 4.7 (3.3, 9.8) 8.4 (4.8, 12.6)
Pazopanib (TK; oral) 631 7.0 (6.0, 8.0) 9.3 (8.2, 10.6)
Axitinib (TK; oral) 56 12.0 (7.4, 18.8) 14.4 (7.7, 22.3)
Bevacizumab (VEGF; IV) 149 2.8 (1.8, 4.4) 22.5 (11.7, NR)
Everolimus (mTOR; oral) 76 4.0 (3.2, 6.1) 8.0 (3.6, 11.3)
Temsirolimus (mTOR; IV) 157 3.9 (3.0, 4.8) 5.7 (4.3, 6.7)
a Kaplan-Meier methods were used. NR not reached
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TT2T was 9.1 months (Table 3). Among the oral agents,
axitinib had the longest median treatment duration
(12.0 months) and median TT2T (14.4 months); everoli-
mus had the shortest median treatment duration (4.0
months) and median TT2T (8.0 months). Among the IV
agents, the median treatment durations of temsirolimus
and bevacizumab were 3.9 and 2.8 months, respectively.
The median TT2T was 5.7 months for temsirolimus and
22.5 months for bevacizumab (Table 3). The flow of
treatment across lines of therapy is shown in Fig. 4. Of
the 1992 patients who received 1 L treatment, 52.8%
(n = 1052) received a 2 L treatment. The median
follow-up durations in patients who did and did not
receive 2 L treatment were 17.2 and 14.4months, respect-
ively. Everolimus was the 2 L drug of choice (15.2% of all
1992 evaluated patients), followed by axitinib (10.7%)
and nivolumab (4.6%). Overall, 28% of all patients re-
ceived 2 L TK/VEGF-directed therapy, and 20% received
2 L mTOR-targeted therapy. Forty-one percent of pa-
tients received oral 2 L therapy, and 12% received IV 2 L
therapy (including nivolumab).
IR and time to potentially treatment-related AEs:
longitudinal analysis
The three most common, potentially treatment-related
AEs occurring during or up to 30 days after 1 L
a
b
Fig. 3 Multivariate analysis. a Odds of receiving 1 L mTOR vs TK/VEGF inhibitors. b Odds of receiving IV vs orally administered treatment. Only
variables found to be significant are plotted. Other variables in the multivariate analysis for the comparison of TK/VEGF inhibitor treatment vs
mTOR inhibitor treatment were not significantly different (age, sex, index years 2013 and 2014 vs 2015, DCCI and nephrectomy). Other variables
in the multivariate analysis for the comparison of oral vs IV administration that did not reach statistical significance were sex, employment status
(active and long-term disability vs retiree), insurance type, DCCI, index years 2013 and 2014 vs 2015 and nephrectomy)
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treatment were nausea/vomiting (127.2 per 100 PY),
hypertension (69.1 per 100 PY) and renal insufficiency
(44.5 per 100 PY) (Table 4). In addition to nausea/vomit-
ing and renal insufficiency, hypertension (in patients
who received oral treatment and those treated with TK/
VEGF inhibitors) and anemia (in patients who received
IV treatment and those treated with mTOR-directed
therapy) were among the four most common AEs when
evaluated separately by treatment categories.
Based on time between the claims indicating the initi-
ation of a drug and the initial AE that may have required
medical attention, substantial latency of onset (median
time to first AE claim) was observed for several poten-
tially treatment-related toxicities in patients treated with
1 L TK/VEGF-directed treatment, including nausea/
vomiting (21 days), fatigue/asthenia (72 days), thyroid
disorders (133 days), abdominal pain (99 days), diarrhea
(108 days), pneumonitis (83 days), hepatitis (154 days),
adrenal insufficiency (119 days), neutropenia (110 days)
and colitis (97 days) (Table 5).
Discussion
As the number of 1 L and 2 L treatment options for
mRCC increases, and the role of effective sequencing of
agents evolves, a thorough understanding of the
treatment patterns and AE profiles of each drug class in
the real-world setting will be critical to providing med-
ical benchmarks, assessing adherence to guidelines and
informing benefit:risk decisions in selecting the appro-
priate mRCC treatment. This retrospective, claims-based
analysis evaluated treatment patterns and AEs among a
large, real-world, US population of patients with mRCC.
A cross-sectional analysis was performed to better
understand the patterns of 1 L treatment initiation over
a 10-year period, and a longitudinal analysis provided
information of treatment choice, baseline correlates
and associated AEs in patients treated in routine
medical practice.
The cross-sectional trend analysis demonstrated that
1 L treatment initiation patterns for mRCC generally
reflected the US Food and Drug Administration ap-
provals and NCCN treatment guidelines, with a few ex-
ceptions. The rapid uptake of the TK-targeting agents
sunitinib (approved in 2006) and pazopanib (approved in
2009) was noted, establishing TK/VEGF-directed treat-
ment as the most widely prescribed drug class initiated
during the study period. Throughout the study period,
oral treatments were also more commonly used than IV
treatments. These patterns of TK/VEGF inhibitors and
oral agents were also recapitulated in the longitudinal
Fig. 4 1 L to 2 L treatment flow in patients with mRCC in the Truven Health MarketScan databases. Possible reasons for patients not receiving 2 L
treatment include still being on 1 L treatment, no requirement for 2 L treatment, refusal of treatment and death, although these cannot be
reliably obtained from the claims database
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Table 4 AE IRs in patients with mRCC by drug class and administration route
Potentially treatment-related
AEs during or < 30 days after
1 L treatmenta
All patients
(N = 1992)
TK/VEGF inhibitor
(n = 1752)
mTOR inhibitor
(n = 233)
Oral
(n = 1674)
IV
(n = 318)
IR per 100 PYa
(Poisson 95% CI)
IR per 100 PYa
(Poisson 95% CI)
IR per 100 PYa
(Poisson 95% CI)
IR per 100 PYa
(Poisson 95% CI)
IR per 100 PYa
(Poisson 95% CI)
Fatigue/asthenia 39.8
(36.3, 43.6)
38.2
(34.5, 42.0)
55.2
(41.7, 70.5)
38.7
(34.9, 42.6)
49.3
(37.8, 62.3)
Hypertension 69.1
(61.3, 77.4)
71.7
(63.3, 80.7)
47.8
(29.2, 71.0)
70.2
(61.9, 79.0)
59.2
(37.9, 85.2)
Diarrhea 28.5
(25.6, 31.6)
29.9
(26.7, 33.2)
13.1
(7.3, 20.5)
30.7
(27.5, 34.1)
13.2
8.0, 19.5)
Hand-foot syndrome 4.1
(3.1, 5.2)
4.0
(3.0, 5.2)
3.1
(0.9, 6.9)
4.0
(3.0, 5.2)
4.4
(1.8, 8.3)
Dyspnea 37.6
(34.1, 41.2)
34.7
(31.3, 38.4)
69.6
(53.4, 88.0)
35.9
(32.3, 39.6)
51.7
(39.9, 65.0)
Nausea/vomiting 127.2
(119.0, 135.6)
114.2
(106.3, 122.4)
364.5
(304.6, 429.8)
119.1
(110.8, 127.6)
209.7
(175.6, 246.8)
Back pain 19.9
(17.5, 22.4)
20.3
(17.8, 23.0)
16.2
(9.7, 24.2)
19.8
(17.3, 22.5)
20.8
(14.0, 28.9)
Pain in extremity/limb discomfort 27.8
(24.9, 30.8)
26.6
(23.6, 29.7)
40.9
(29.6, 54.0)
27.1
(24.1, 30.3)
33.0
(24.1, 43.4)
Abdominal pain 31.2
(28.1, 34.5)
30.6
(27.4, 34.0)
35.8
(25.1, 48.4)
32.0
(28.7, 35.6)
25.0
(17.3, 34.1)
Anemia 40.3
(36.6, 44.1)
35.4
(31.8, 39.1)
100.3
(79.1, 123.9)
37.9
(34.1, 41.8)
61.6
(48.0, 76.9)
Hypophosphatemia 1.7
(1.1, 2.5)
1.5
(0.9, 2.2)
2.3
(0.5, 5.6)
1.5
(0.9, 2.3)
3.1
(1.0, 6.4)
Neutropenia 3.9
(3.0, 5.0)
4.2
(3.1,5.3)
1.6
(0.2, 4.3)
4.2
(3.1, 5.4)
1.9
(0.4, 4.5)
Lymphopenia 0.2
(0.0, 0.5)
0.1
(0.0, 0.3)
1.6
(0.2, 4.3)
0.2
(0.0, 0.4)
0.6
(0.0, 2.3)
Hypotension 7.7
(6.3, 9.3)
7.6
(6.2, 9.2)
7.2
(3.3, 12.7)
7.6
(6.1, 9.3)
8.6
(4.6, 13.8)
Proteinuria 5.2
(4.1, 6.5)
5.0
(3.9, 6.3)
7.3
(3.4, 12.9)
4.7
(3.6, 5.9)
9.8
(5.5, 15.4)
Thrombocytopenia 3.0
(2.2, 3.9)
3.0
(2.2, 4.1)
2.3
(0.5, 5.6)
3.1
(2.2, 4.1)
1.9
(0.4, 4.5)
Hepatitis 9.3
(7.7, 11.1)
9.1
(7.5, 11.0)
11.0
(5.7, 18.1)
9.7
(7.9, 11.6)
6.3
(2.9, 11.0)
Thyroid disorders 21.2
(18.6, 24.0)
21.9
(19.1, 24.9)
14.9
(8.5, 23.0)
22.9
(20.0, 26.0)
9.5
(5.0, 15.3)
Renal insufficiency 44.5
(38.9, 50.5)
42.3
(36.6, 48.4)
60.8
(38.9, 87.4)
43.0
(37.2, 49.3)
58.3
(39.0, 81.3)
Adrenal insufficiency 6.3
(5.0, 7.7)
5.8
(4.5, 7.2)
10.4
(5.4, 17.0)
5.9
(4.6, 7.4)
9.1
(4.8, 14.6)
Pneumonitis 27.3
(24.4, 30.2)
24.6
(21.8, 27.6)
56.2
(42.4, 71.8)
25.2
(22.4, 28.3)
43.6
(33.3, 55.3)
Colitis 0.5
(0.2, 0.9)
0.5
(0.2, 0.9)
0.8
(0.0, 2.9)
0.4
(0.1, 0.8)
1.3
(0.2, 3.5)
Guillain-Barré syndrome 0.1
(0.0, 0.3)
0.1
(0.0, 0.3)
0 0.1
(0.0, 0.3)
0
Meningoencephalitis 0.5
(0.2, 0.9)
0.5
(0.2, 1.0)
0 0.5
(0.2, 0.9)
0.6
(0.0, 2.3)
Myasthenia gravis 0 0 0 0 0
Rash 10.1
(8.5, 11.9)
9.5
(7.9, 11.3)
14.3
(8.4, 21.9)
9.9
(8.2, 11.7)
11.9
(7.1, 18.0)
a Washout period of 30 days prior to the index date was applied when identifying incidence events for all AEs, except for chronic conditions, where a
365-day washout period was applied. If a patient did not have an event, their person-time was counted up to 30 days after the end of first-line
treatment or the end of eligibility, whichever occurred first
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Table 5 Time to onset of AEs by drug class and route of administration
Adverse event All patients
(N = 1992)
TK/VEGF inhibitor
(n = 1752)
mTOR inhibitor
(n = 233)
Oral
(n = 1674)
IV
(n = 318)
Median, days
(Q1–Q3)
Median, days
(Q1–Q3)
Median, days
(Q1–Q3)
Median, days
(Q1–Q3)
Median, days
(Q1–Q3)
Fatigue/asthenia 72.0
(29.0, 157.0)
74.0
(28.0, 168.0)
63.0
(35.5, 119.0)
74.0
(28.0, 165.0)
58.5
(29.0, 118.0)
Hypertension 72.0
(28.0, 156.0)
70.0
(28.0, 151.0)
116.5
(42.0, 240.5)
72.0
(29.0, 163.0)
76.5
(11.5, 138.5)
Diarrhea 108.0
(45.0, 211.0)
111.0
(48.5, 215.5)
46.0
(25.0, 194.0)
110.0
(48.0, 214.0)
46.5
(21.5, 194.5)
Hand-foot syndrome 93.5
(43.0, 218.0)
109.0
(54.0, 231.5.0)
30.0
(20.5, 53.0)
112.0
(57.0, 241.0)
30.0
(10.0, 33.0)
Dyspnea 88.0
(28.0, 210.0)
94.0
(29.0, 227.0)
68.5
(23.0, 156.0)
95.0
(31.0, 226.0)
52.0
(20.0, 146.0)
Nausea/vomiting 21.0
(4.0, 78.0)
27.0
(7.0, 89.0)
0 28.0
(8.0, 90.0)
0
Back pain 90.0
(31.0, 198.0)
90.5
(34.0, 197.50)
89.0
(22.0, 287.0)
93.0
(34.0, 198.0)
75.0
(20.0, 196.0)
Pain in extremity/limb discomfort 112.0
(46.0, 238.0)
113.0
(44.0, 238.0)
95.0
(48.0, 240.0)
113.0
(46.5, 246.0)
83.0
(44.0, 165.0)
Abdominal pain 98.5
(35.0, 226.5)
104.5
(36.0, 229.0)
87.0
(32.5, 195.0)
104.5
(37.0, 229.0)
63.5
(30.0, 176.0)
Anemia 85.0
(32.5, 183.5)
93.0
(35.0, 200.0)
66.0
(26.0, 132.0)
93.5
(35.0, 201.0)
64.5
(18.0, 118.0)
Hypophosphatemia 100.0
(56.0, 138.0)
102.0
(60.0, 136.5)
299.0
(43.0, 498.0)
110.0
(60.0, 146.0)
43.0
(9.0, 104.0)
Neutropenia 110.0
(47.5, 242.5)
117.0
(48.0, 245.0)
37.5
(19.0, 56.0)
115.0
(48.0, 240.0)
56.0
(19.0, 465.0)
Lymphopenia 108.0
(95.0, 136.0)
95.0
(95.0, 95.0)
122.0
(108.0, 136.0)
115.5
(95.0, 136.0)
108.0
(108.0, 108.0)
Hypotension 105.0
(42.0, 222.0)
117.5
(44.0, 239.0)
58.0
(51.0, 179.0)
111.0
(43.0, 230.0)
56.0
(41.0, 191.0)
Proteinuria 80.5
(29.0, 245.0)
84.0
(30.0, 235.0)
56.0
(26.0, 257.0)
108.0
(41.0, 336.0)
30.0
(20.0, 84.0)
Thrombocytopenia 97.0
(50.0, 188.0)
93.5
(48.5, 194.0)
112.0
(52.0, 140.0)
87.0
(48.5, 187.0)
140.0
(112.0, 256.0)
Hepatitis 154.0
(71.0, 256.0)
148.0
(71.0, 253.0)
209.0
(128.0, 326.0)
150.5
(71.0, 256.0)
190.0
(166.0, 234.0)
Thyroid disorders 133.0
(75.0, 256.0)
134.0
(79.0, 259.0)
91.0
(55.0, 196.0)
133.5
(79.0, 259.0)
131.0
(62.0, 175.0)
Renal insufficiency 94.0
(33.0, 217.0)
95.0
(39.5, 225.5)
90.5
(18.0, 62.5)
97.0
(41.0, 231.0)
61.0
(14.0, 133.0)
Adrenal insufficiency 119.0
(69.0, 213.0)
108.0
(67.0, 227.0)
147.0
(118.0, 200.0)
110.0
(70.0, 218.0)
132.0
(4.0, 201.0)
Pneumonitis 83.0
(29.0, 209.0)
87.0
(31.0, 223.0)
73.5
(21.5, 155.5)
90.0
(31.0, 223.0)
68.5
(19.5, 150.5)
Colitis 97.0
(43.0, 139.0)
101.5
(66.0, 139.0)
0 106.0
(97.0, 139.0)
21.5
(0.0, 43.0)
Guillain-Barré syndrome 52.0
(52.0, 52.0)
52.0
(52.0, 52.0)
0 52.0
(52.0, 52.0)
0
Meningoencephalitis 122.0
(75.0, 159.0)
122.0
(75.0, 159.0)
0 112.0
(75.0, 159.0)
122.0
(122.0, 122.0
Myasthenia gravis 0 0 0 0 0
Rash 79.0
(37.5, 214.0)
83.0
(44.0, 220.0)
55.0
(23.0, 149.0)
82.5
(47.0, 213.0)
28.0
(10.0, 224.0)
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analysis. These findings are consistent with those from
studies detailing the widespread use of TK inhibitors
[26], and the less frequent use of sorafenib and axitinib
in the 1 L setting is also consistent with NCCN recom-
mendations for these TK inhibitors [8]. Of note was the
finding that the use of bevacizumab as monotherapy was
more prevalent than as combination therapy with IFN-α.
These findings suggest that increased costs and
IFN-related toxicities may render bevacizumab more at-
tractive as monotherapy than as combination therapy
with IFN [27]. Moreover, Phase II data support the use of
bevacizumab as 1 L treatment and salvage therapy [28,
29]. Additionally, a considerable number of patients re-
ceived everolimus in the 1 L setting despite the lack of in-
dication in this setting, which reflects the wide variability
seen in provider preference and clinical experience.
Provider preferences, patient history and known toxic-
ities associated with drug classes may drive 1 L treat-
ment choice, although it is difficult to ascertain from
claims data which characteristics influenced the specific
choices of mRCC treatment. In this study, CHF and a
DCCI score ≥ 4 were independent predictors of IV treat-
ment choice, while patients with lung metastases were
less likely to receive IV treatment than were those with-
out lung metastases. Patients with diabetes were less
likely to receive mTOR-directed therapy, while patients
with comorbid CHF, liver metastases or bone metastases
were more likely to receive mTOR-directed therapy.
These data are in agreement with the known cardiotoxi-
city associated with both sunitinib and pazopanib [23,
25], such as cardiac dysfunction (sunitinib, 11% fre-
quency; pazopanib, 13%) and myocardial infarction/is-
chemia (sunitinib, 4% frequency; pazopanib, 2%) [11].
Similarly, a preference for TK/VEGF inhibitors in those
with diabetes can be explained by the fact that hypergly-
cemia is a well-known AE associated with mTOR
inhibitors (observed in 26% of patients treated with tem-
sirolimus [30] and 50% treated with everolimus [31]) .
Duration of treatment also varies by agent and may in-
fluence treatment choice. Median duration of TK/
VEGF-directed treatment was much longer than that of
mTOR-directed treatment (6.3 and 3.9 months); simi-
larly, oral treatment duration was nearly twice that of IV
treatment (6.6 and 3.4 months). The median durations
of sunitinib and pazopanib treatment were similar to
each other (6.5 and 7.0 months, respectively), but were
longer than those of sorafenib (4.7 months), everolimus
(4.0 months), and temsirolimus (3.9 months). Reported
results of real-world studies are mixed. For example, the
observed sunitinib and sorafenib treatment durations
were similar to those reported by Feinberg et al. (5.9 and
5.5 months, respectively) [32] and only slightly longer
than those reported by Miller et al. (5.6 and 5.3 months,
respectively), who also reported durations of 5.3 months
for pazopanib and 4.5 months for everolimus [14]. How-
ever, these durations are slightly longer than those re-
ported by Hess et al. (3.2 and 4.0 months, respectively;
2.6 months for temsirolimus) [33] and Vogelzang et al.
(sunitinib, 4.1 months; pazopanib 4.8 months) [15]. How-
ever, it should be noted that direct cross-study compari-
sons are not possible based on different analysis
methods and populations. Treatment durations reported
in the randomized clinical trial setting are also some-
times mixed and are not dissimilar to the results from
this study. For instance, Phase III data have shown 1 L
median treatment durations of 7.6 and 8.0 months, re-
spectively, for TK inhibitors sunitinib and pazopanib
[11] and 3.9 months for the mTOR inhibitor temsiroli-
mus [30]. Collectively, these data suggest that there are
potential differences in patient selection, outcomes
measurement and patient preference between real-world
data studies and randomized clinical trials that could
have implications for future clinical trial design. These
differences may reflect the difficulty in (1) maintaining
adequate dosing with these relatively toxic agents and
(2) reproducing clinical trial results in the real-world set-
ting for mRCC.
Potential differences in toxicities between the 1 L treat-
ments in this study vs those previously seen were also
evaluated, and it was noted that the most common AEs
associated with each drug class were generally consistent
with previously reported results [34–37] and with the
product labels [19–25]. Notably, however, substantial la-
tency of onset was observed for several potentially
treatment-related toxicities in patients treated with both
TK/VEGF- and mTOR-inhibitor classes, which was
much different in clinical practice (i.e., onset of fatigue,
hypertension and hepatic dysfunction generally occurs
quickly). AE latency in the database may be due to cap-
ture of only the toxicities that generate a medical claim
and may suggest that the toxicities that are observed
early on may not receive medical care in clinical prac-
tice. There were also AEs potentially associated with
checkpoint inhibitors. The latency of these AEs was simi-
lar to that observed with checkpoint inhibitors [38, 39].
These results suggest that attributing toxicities to TK/
VEGF-directed therapies vs checkpoint inhibitors, when
used in combination, may be challenging due to overlap-
ping toxicities.
In contrast to the 1 L treatment data, 2 L treatment
data were less defined. In this study, nearly half of all pa-
tients did not have evidence of receiving 2 L treatment
(47% [n = 940]); however, there is no reliable way to de-
termine the reasons for this from a claims database. Pa-
tients who did not receive 2 L therapy in this study may
either still be receiving 1 L targeted therapy (and were
not captured in the study due to the follow-up period
ending) or have attained sustained remission, died before
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receiving 2 L therapy, refused 2 L treatment or did not
receive 2 L therapy for unknown reasons. Consistent
with other studies, most patients treated with a 1 L oral
TK inhibitor who received 2 L therapy were switched to
2 L mTOR-directed treatment, primarily everolimus
[26]; 2 L treatment choice warrants further investigation.
This study had several strengths and limitations.
Strengths include the large number of 1 L–treated pa-
tients with mRCC over time, including those treated
with TK/VEGF- or mTOR-directed therapy. The use of
the MarketScan databases also provided strength to this
study due to the inclusion of the full continuum of care
in all inpatient and outpatient settings, as well as retail
and specialty pharmacies, and the longitudinal tracking
of patient information. However, the MarketScan data-
bases also have limitations, as they are inherently re-
stricted to insured patients and provide limited social
background and demographic data. Secondary metasta-
sis codes were not required for identification of patients
with mRCC since the 1 L treatments are approved in the
metastatic setting only and to avoid exclusion of eligible
patients due to potential underreporting of secondary
metastasis codes. However, the study could have in-
cluded patients who received the treatments off-label in
the adjuvant/neoadjuvant setting. Further, administrative
claims-based data are prone to coding and data entry er-
rors. Potential underreporting of secondary metastasis
and baseline comorbidities may have affected the point
estimates in the multivariate models, and the distribu-
tion of these variables may not be representative of the
RCC population in clinical practice. Moreover, only AEs
of sufficient severity to prompt medical attention and
generate a claim could be identified, which may have led
to underreported IRs. It was also not possible to discern
from the claims data whether an AE was reported due
to a drug reaction, RCC progression or other cause, nor
was it possible to know the severity/grade of the AE.
Further, it is unknown from the claims data whether 2 L
treatment was received due to toxicity or disease pro-
gression. In this study, the treatment duration end date
was calculated by adding the days’ supply of oral treat-
ment and cycle length for IV treatment. Since most pa-
tients receive their oral drug supply 1 to 3 months in
advance, the treatment duration for oral medications
may have been overestimated. Additionally, the propor-
tion of patients who switched treatment may have been
underreported due to the limited follow-up in this study
(median of ≈ 16 months after the index date). However,
this median follow-up may be of limited concern consider-
ing the low survival rates in this patient population [40, 41].
Lastly, recent approvals (e.g., cabozantinib and nivolumab ±
ipilimumab) and treatment recommendations were not cap-
tured given that these agents were not approved during the
period covered by the analysis [42–44].
Conclusions
In this retrospective, claims-based study of patients with
mRCC in the Truven Health MarketScan databases,
10-year prescribing trends showed the transition from
cytokine-based treatment to targeted agents and a simi-
lar shift from IV to oral agents. Observed 1 L treatment
patterns generally suggested good adherence to NCCN
guideline recommendations, although treatment dura-
tions across the literature appear variable. In all patients
and those treated with TK/VEGF- and mTOR-directed
1 L treatment, the three most common AEs were hyper-
tension, nausea/vomiting and renal insufficiency. The 2 L
treatments included a wide variety of agents for mRCC.
With new agents and combinations (e.g., checkpoint in-
hibitor therapy) emerging following this study period
(through 2016), these data will be useful in providing
medical benchmarks for contemporary mRCC therapy.
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